Retrospective Epidemiology Study Of ALK Rearrangement In Non-Small Cell Lung Cancer Patients In The Middle East & North Africa

NCT02304406

Last updated date
Study Location
National Cancer Institute
Cairo / Misr Al Qadimah, , , Egypt
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Non-small Cell Lung Cancer
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- 1. Histological confirmation of nonsquamous NSCLC, with any TNM stage. 2. Available and sufficient tissue sample for ALK testing 3.Tissue samples are less than 5 years old 4.Routinely processed formalin-fixed, paraffin-embedded tissue samples only (see exclusion criteria pertaining to tissue samples).

5.Histological sections mounted on glass slides must not be older than 3 months 6.Age > 18 years 7.Any ECOG Performance status 8.Still alive, or death confirmed before inclusion, or is unknown 9.Disease diagnosis and/or treatment in one of the centers, in the last 5 years, assigned to participate in the study; 10.Written informed consent for general investigational testing was previously obtained, or specifically obtained for this retrospective epidemiology study, or having a documented waiver for the Informed consent document use, as required by local regulatory authorities, &/or Research Ethics committee/Institutional Review Board.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- 1- Tumor tissue samples older than 5 year period or samples not properly stored.


2-Tumor tissue samples fixed by using AFA, B5, Bouin's, 95% ETOH, & alcohol fixatives.


3-Under-fixed tissue samples (i.e. < 6 hrs) 4-Tumor tissue samples that have been
subject to any decalcification processes. 5-Recycled paraffin-embedded tissue samples.
6-Cut slides stored longer than 3 months. 7-Insufficient tissue samples with less
tumor cells & high amount of necrosis.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Non-Small Cell Lung CancerStudy of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC (UF-STO-LUNG-002)
NCT02920450
  1. Gainesville, Florida
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Non-Small Cell Lung CancerEffect of Celecoxib on Survival in Patients With Advanced Non-Small Cell Lung Cancer Receiving Chemotherapy
NCT00300729
  1. Gothenburg,
  2. Jönköping,
  3. Kalmar,
  4. Linköping,
  5. Lund,
  6. Malmö,
  7. Skövde,
  8. Trollhättan,
  9. Uddevalla,
  10. Umeå,
  11. Uppsala,
  12. Ystad,
  13. Örebro,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Non-Small Cell Lung CancerA Phase I Study of SUNITINIB and Rapamycin in Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT00555256
  1. St. Louis, Missouri
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Non-small Cell Lung CancerAn Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600E-mutant Non-small Cell Lung Cancer
NCT03915951
  1. Altamonte Springs, Florida
  2. Bonita Springs, Florida
  3. Bradenton, Florida
  4. Brandon, Florida
  5. Cape Coral, Florida
  6. Clearwater, Florida
  7. Fleming Island, Florida
  8. Fort Myers, Florida
  9. Fort Myers, Florida
  10. Gainesville, Florida
  11. Largo, Florida
  12. Lecanto, Florida
  13. Naples, Florida
  14. New Port Richey, Florida
  15. Ocala, Florida
  16. Orange City, Florida
  17. Orlando, Florida
  18. Port Charlotte, Florida
  19. Saint Petersburg, Florida
  20. Sarasota, Florida
  21. Sarasota, Florida
  22. Spring Hill, Florida
  23. Tallahassee, Florida
  24. Tampa, Florida
  25. Tavares, Florida
  26. The Villages, Florida
  27. Venice, Florida
  28. Winter Park, Florida
  29. Atlanta, Georgia
  30. Atlanta, Georgia
  31. Atlanta, Georgia
  32. Johns Creek, Georgia
  33. Overland Park, Kansas
  34. Baltimore, Maryland
  35. Baltimore, Maryland
  36. Creve Coeur, Missouri
  37. Independence, Missouri
  38. Kansas City, Missouri
  39. Saint Louis, Missouri
  40. Saint Louis, Missouri
  41. Saint Louis, Missouri
  42. New York, New York
  43. New York, New York
  44. Durham, North Carolina
  45. Columbus, Ohio
  46. Columbus, Ohio
  47. Columbus, Ohio
  48. Columbus, Ohio
  49. Columbus, Ohio
  50. Columbus, Ohio
  51. Columbus, Ohio
  52. Gahanna, Ohio
  53. Lewis Center, Ohio
  54. Clackamas, Oregon
  55. Newberg, Oregon
  56. Chattanooga, Tennessee
  57. Cleveland, Tennessee
  58. Dickson, Tennessee
  59. Franklin, Tennessee
  60. Gallatin, Tennessee
  61. Hendersonville, Tennessee
  62. Hermitage, Tennessee
  63. Lebanon, Tennessee
  64. Murfreesboro, Tennessee
  65. Nashville, Tennessee
  66. Nashville, Tennessee
  67. Nashville, Tennessee
  68. Nashville, Tennessee
  69. Shelbyville, Tennessee
  70. Smyrna, Tennessee
  71. Kingwood, Texas
  72. The Woodlands, Texas
  73. Roma, Lazio
  74. Orbassano, Torino
  75. Orbassano, Torino
  76. Orbassano, Torino
  77. Orbassano, Torino
  78. Orbassano, Torino
  79. Orbassano, Torino
  80. Napoli,
  81. Torino,
  82. Barcelona,
  83. Cordoba,
  84. Cordoba,
  85. Esplugues de Llobregat,
  86. L'Hospitalet,
  87. Malaga,
  88. Sevilla,
  89. Los Angeles, California
  90. Santa Monica, California
  91. Norwich, Connecticut
  92. Norwich, Connecticut
  93. Norwich, Connecticut
  94. Putnam, Connecticut
  95. Fort Myers, Florida
  96. Saint Petersburg, Florida
  97. Tallahassee, Florida
  98. Venice, Florida
  99. Atlanta, Georgia
  100. Chicago, Illinois
  101. Overland Park, Kansas
  102. Baltimore, Maryland
  103. Baltimore, Maryland
  104. Boston, Massachusetts
  105. Boston, Massachusetts
  106. Boston, Massachusetts
  107. Boston, Massachusetts
  108. Boston, Massachusetts
  109. Boston, Massachusetts
  110. Chelsea, Massachusetts
  111. Danvers, Massachusetts
  112. Marlborough, Massachusetts
  113. Stoneham, Massachusetts
  114. Stoneham, Massachusetts
  115. Waltham, Massachusetts
  116. Independence, Missouri
  117. Kansas City, Missouri
  118. Saint Louis, Missouri
  119. Basking Ridge, New Jersey
  120. Hackensack, New Jersey
  121. Montvale, New Jersey
  122. Bronx, New York
  123. Bronx, New York
  124. Bronx, New York
  125. New York, New York
  126. New York, New York
  127. New York, New York
  128. New York, New York
  129. Portland, Oregon
  130. Portland, Oregon
  131. Pittsburgh, Pennsylvania
  132. Pittsburgh, Pennsylvania
  133. Pittsburgh, Pennsylvania
  134. Pittsburgh, Pennsylvania
  135. York, Pennsylvania
  136. York, Pennsylvania
  137. Chattanooga, Tennessee
  138. Chattanooga, Tennessee
  139. Houston, Texas
  140. Houston, Texas
  141. Shenandoah, Texas
  142. Seattle, Washington
  143. Faenza, Emilia-romagna
  144. Lugo, Emilia-romagna
  145. Ravenna, Emilia-romagna
  146. Ravenna, Emilia-romagna
  147. Rimini, Emilia-romagna
  148. Milano, Lombardia
  149. Milano, Lombardia
  150. Napoli, Naples
  151. Cattolica, Rimini
  152. Orbassano, Torino
  153. Bologna,
  154. Milano,
  155. Naples,
  156. Goyang-si, Gyeonggido
  157. Jeonnam,
  158. Seoul,
  159. Seoul,
  160. Seoul,
  161. Amsterdam, Noord-holland
  162. Amsterdam, Noord-holland
  163. Groningen,
  164. Hospitalet de Llobregat, Barcelona
  165. L'Hospitalet de Llobregat, Barcelona
  166. L'Hospitalet de Llobregat, Barcelona
  167. Majadahonda, Madrid
  168. Malaga, Málaga
  169. Barcelona,
  170. Barcelona,
  171. Barcelona,
  172. Barcelona,
  173. Hospitalet de Llobregat,
  174. Madrid,
  175. Madrid,
  176. Sevilla,
  177. Sevilla,
  178. Sevilla,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title Retrospective Epidemiology Study Of ALK Rearrangement In Non-Small Cell Lung Cancer Patients In The Middle East & North Africa
Official Title RETROSPECTIVE EPIDEMIOLOGY STUDY OF ALK REARRANGEMENT IN NON-SMALL CELL LUNG CANCER PATIENTS IN THE MIDDLE EAST & NORTH AFRICA.
Brief Summary Thet study aims to estimate the prevalence of ALK rearrangement in the Middle East North Africa population by using the Ventana ALK-IHC method for ALK protein detection in retrospective NSCLC clinical samples, & to evaluate the association of ALK rearrangement with clinical and pathological parameters of NSCLC patients in MENA.
Detailed Description

This is a retrospective, cross-sectional non-interventional epidemiology study to investigate the prevalence of ALK rearrangement in NSCLC patients in Middle East & North Africa. Approximately 700 retained tumor tissue specimens (tissue block) of patients previously diagnosed with NSCLC will be selected & subjected to ALK immune-staining using Ventana anti-ALK (D5F3) Rabbit Monoclonal Primary Antibody combined with OptiView Benchmark System in 6-8 centers in 5-7 countries in the MENA region.

The tissue samples of NSCLC cases will be retrieved from tissue banks of the molecular diagnostic units & pathology departments in these study centers. The histological diagnosis will be confirmed by the pathologists. The retained samples will then be tested by performing the Ventana ALK-IHC to assess the absence or presence of the ALK rearrangement by the detection of the ALK protein in formalin-fixed, paraffin-embedded NSCLC stored tissue samples using Ventana anti-ALK (D5F3) Rabbit Monoclonal Primary Antibody (Roche Diagnostics GmbH) in the selected study centers. The results of ALK testing within this study population will then be used to establish the prevalence of ALK rearrangement in MENA NSCLC patients.

The patients' characteristics, demographic, clinical and pathologic parameters will be obtained from their medical records & analyzed to determine any association with the presence of the EML4-ALK fusion gene in MENA NSCLC patients.

The assessment of concordance of the results between FISH & IHC will be done in 2-3 centers. Results of FISH testing will be collected & recorded, if the retained tissue samples had been previously tested. If not, the Vysis FISH test will be performed, to assess the concordance between the results obtained using Vysis Break-apart FISH & Ventana IHC testing methods for ALK rearrangement detection.

Study Type Observational
Study Design Observational Model: Other
Time Perspective: Retrospective
Target Follow-Up Duration Not Provided
Biospecimen Retention:   Samples With DNA
Description:
The tissue samples of NSCLC cases will be retrieved from tissue banks of the molecular diagnostic units & pathology departments in these study centers. The histological diagnosis will be confirmed by the pathologists. The retained samples will then be tested by performing the Ventana ALK-IHC to assess the absence or presence of the ALK rearrangement by the detection of the ALK protein in formalin-fixed, paraffin-embedded NSCLC stored tissue samples using Ventana anti-ALK (D5F3) Rabbit Monoclonal Primary Antibody (Roche Diagnostics GmbH) in the selected study centers.
Sampling Method Non-Probability Sample
Study Population Since this is a retrospective epidemiology study, no patients will be enrolled. Tissue samples of non-squamous NSCLC cases less than 5 years old from each of the centers will be selected.
Condition Non-small Cell Lung Cancer
Intervention Not Provided
Study Groups/Cohorts Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Completed
Actual Enrollment
 (submitted: October 24, 2018)
449
Original Estimated Enrollment
 (submitted: December 1, 2014)
700
Actual Study Completion Date February 11, 2018
Actual Primary Completion Date February 11, 2018   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

- 1. Histological confirmation of nonsquamous NSCLC, with any TNM stage. 2. Available and sufficient tissue sample for ALK testing 3.Tissue samples are less than 5 years old 4.Routinely processed formalin-fixed, paraffin-embedded tissue samples only (see exclusion criteria pertaining to tissue samples).

5.Histological sections mounted on glass slides must not be older than 3 months 6.Age > 18 years 7.Any ECOG Performance status 8.Still alive, or death confirmed before inclusion, or is unknown 9.Disease diagnosis and/or treatment in one of the centers, in the last 5 years, assigned to participate in the study; 10.Written informed consent for general investigational testing was previously obtained, or specifically obtained for this retrospective epidemiology study, or having a documented waiver for the Informed consent document use, as required by local regulatory authorities, &/or Research Ethics committee/Institutional Review Board.

Exclusion Criteria:

  • 1- Tumor tissue samples older than 5 year period or samples not properly stored.

    2-Tumor tissue samples fixed by using AFA, B5, Bouin's, 95% ETOH, & alcohol fixatives.

    3-Under-fixed tissue samples (i.e. < 6 hrs) 4-Tumor tissue samples that have been subject to any decalcification processes. 5-Recycled paraffin-embedded tissue samples. 6-Cut slides stored longer than 3 months. 7-Insufficient tissue samples with less tumor cells & high amount of necrosis.

Sex/Gender
Sexes Eligible for Study:All
Ages 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Egypt,   Lebanon,   Morocco,   Saudi Arabia,   United Arab Emirates
Removed Location Countries  
 
Administrative Information
NCT Number NCT02304406
Other Study ID Numbers A8081046
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement
Plan to Share IPD:No
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d….
Responsible Party Pfizer
Study Sponsor Pfizer
Collaborators Not Provided
Investigators
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date May 2019